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Administration of a tumour-seeking comgiven. At laparotomy, a search was made with pound labeled with a low-energy isotope and the gamma probe for areas of increased activity. intraoperative screening with the gamma probe
The gamma probe correctly identified active (radioguided surgery, RGS) could be useful in neuroblastoma tissue that was seen on the prereoperations for advanced neuroblastoma when operative MIBG scan. There appeared to be a the normal anatomy is altered. A pilot study was relationship between intensity of radioactivity performed to test the feasibility of this technique.
and degree of maturation on histologic examinaFive patients underwent six relaparotomies for tion. This pilot study shows that RGS with MIBG recurrent stage III or IV neuroblastoma. All had and intraoperative use of the gamma probe is been treated with intensive chemotherapy and/ able to identify recurrent neuroblastoma. or metaiodobenzylguanidine (MIBG)-I 131 with or Whether this method is able to detect occult without hyperbaric oxygen. Reoperation was tumour and whether RGS will result in better performed to achieve near-total (greater than outcome are the subjects of ongoing research. 95%) excision. In all instances, active tumour Key words: neuroblastoma; radioguided surgery; metaiodobenzylguanidine (MIBG); gamma probe ation was performed to achieve near-total (greater than INTRODUCTION 95%) excision. In all instances, active tumour was seen Reoperations for advanced neuroblastoma are indi-on the preoperative diagnostic MIBG scan. Ultrasound cated when the primary operation was irradical and post-(US), computerized tomography (CT) scan, or magnetic operative chemotherapy has achieved sufficient reduction resonance imaging (MRI) interpretations were hampered to allow successful reexcision. Alternatively, recurrence by the previous operations. Two days before surgery, a after initial macroscopic complete excision may necessi-tracer dose of MIBG-I 123 was given (185 mBeq). After tate reoperation. In these cases, it can be difficult to opening of the abdominal cavity and lysis of adhesions, identify the exact localisation of tumour tissue because a full exploration was performed, with the careful noting of altered anatomy. Administration of a tumour-seeking of all visible and/or palpable abnormalities. As a schecompound labeled with a low-energy isotope and intraop-matic aid, the abdomen was divided into four areas: the erative screening with a gamma probe (radioguided sur-liver, the upper abdomen cranially from the transverse gery, RGS) may be helpful. This technique has been mesolocon, the lower abdomen bordered by the colon, applied successfully in colorectal and breast cancer using and the pelvis below the promontory. Subsequently, the radioimmunolabeling [1] [2] [3] . In neuroblastoma, vital tu-four parts of the abdomen were scanned consecutively mour cells are known to take up metaiodobenzylguanid-with a hand-held gamma probe (Figs. 1 and 2; Neoprobe ine (MIBG). Radioactive MIBG, labeled with I 131 or I 123 , 1000; Neoprobe Corp., Columbus OH) packed in a sterile is applied for diagnostic and therapeutic purposes [4, 5] . cover. In addition, any suspicious area is screened with A pilot study was performed to test the feasibility of the gamma probe. Background counts are recorded at the using MIBG and the gamma probe for intraoperative localisation of neuroblastoma. vein. The highest mean counts were recorded. The exact size of the tumour was not always easy to estimate because of surrounding fibrosis.
Any clinically suspicious tissue-with or without elevated gamma counts-was excised. Tissues with elevated gamma counts without clinical suspicion were, whenever visible, biopsied for microscopic examination. After complete excision, the tumour bed was scanned for any residual activity.
The highest tumour counts related to the background normal tissue counts were recorded. Ex vivo tissue counts by a well counter were not performed. The exact amount of tumour-containing tissue was clinically difficult to assess as a result of surrounding fibrosis.
Minimal standard measurements were taken after the study protocol as shown in Figure 1 . A tumour to background ratio of 2 or more was considered significant. For maximal reproducibility, it was important that the position of the probe was moved slowly over the examined tissue after squelching of the background radiation. Counts per 2 seconds were taken from the regions of interest and recorded on the protocol form. standard locations of the mid-ileum, right and left liver lobes, and spleen after surgical exposure. Background RESULTS activity is determined by the tissue that is scanned; if liver tissue is explored, the probe counts on apparently
The gamma probe correctly identified active neuroblastoma tissue that was seen on the preoperative MIBG normal tissue are squelched to zero. All counts higher than the background are recognized by an audible siren scan. In Patient D, a persistent area of increased activity was seen near the right kidney without macroscopic abproduced by the probe. Para-aortal or paracaval tissue is scanned after measuring background activity in the caval normality. No tissue was excised in this area because that related to the histology of the tumour. An inherent problem of recurrent neuroblastoma is distinguishing between fibrotic tissue and tumour. Inevitably, some amount of could have endangered the blood supply to the kidney. fibrous tissue will be included during excision, which After 9 months, tumour relapse in this area was confirmed makes it difficult to explore the correlation between tuat reoperation, in which the gamma probe was used. In mour size and radioactivity as measured by the gamma the same patient, US revealed a mass that was not shown probe. Considering our positive clinical experience with on the MIBG scan. The gamma probe demonstrated no these five patients, further study is warranted. This RGS increased activity, and the mass appeared to be a lymphosystem with I 123 MIBG might be helpful. cele. This lymphocele was discovered during the first Concerning the safety of RGS using a tracer dose of relaparotomy in which we used the gamma probe. The I 123 , it is clear that the use of I 123 is not a radiation risk. area with increased activity near the right kidney found
The half-life of I 123 is 13.2 hours, and this isotope is a at this procedure revealed no macroscopic tumour at that low-energy inhibitor of 159 Kev. With the administration time, but was found to be the site of relapse 9 months later.
The intensity of radioactivity varied considerably (Ta-of a tracer dose of 185 mBeq, the gamma radiation expoble II). From these data, there appears to be a correlation sure is extremely low, with minimal hazard for the patient, between the number of counts in situ and the degree of surgeon, or operating room personnel. Even the use of maturity on histologic examination. I 125 (energy 35 Kev isotope with a half-life of 60.2 days) with larger doses does not produce any significant radia-DISCUSSION tion risk [6] . This pilot study shows that it is possible to identify recurrent neuroblastoma with RGS with a tracer dose of CONCLUSIONS I 123 MIBG and intraoperative use of the gamma probe. From this limited experience, we can conclude that In one patient, RGS-positive localisation without clinical the method is both specific and sensitive for the detection evidence of tumour appeared to be the site of tumour of neuroblastoma. Ongoing research will be needed to recurrence, confirmed by relaparotomy 9 months later. During the initial laparotomy, a cyst-like structure in the analyze the relationship between radioactivity and histol-4. Hoefnagel CA, Vo'te PA, de Kraker J, Marcuse HR: Radionuclide ogy. It still has to be demonstrated that this technique diagnosis and therapy of neural crest tumors using iodine-131 metahas a beneficial effect on outcome.
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